Prescription medication · NS3/4A/NS5A Inhibitor (HCV)

glecaprevir/pibrentasvir

Also sold as Mavyret. Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6.

Data updated 2026-05-15

8,300
FDA reports
38
InteractionsSeveral interactions
$152.83
Brand price (NADAC)

What the data shows

glecaprevir/pibrentasvir (Mavyret) is a prescription NS3/4A/NS5A Inhibitor (HCV), with 8,300 FDA adverse-event reports on file, with 38 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

glecaprevir/pibrentasvir (Mavyret) is a prescription NS3/4A/NS5A Inhibitor (HCV). Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6.

Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.

Verify with FDA → · CMS NADAC pricing →

Drug Pricing (NADAC)

Brand Price

$152.83/unit

Generic Available

No

ABBVIE

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

Compare with Another Drug →

What it does

Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6.

Common side effects

Headache, Feeling tired, Nausea

Key warnings

Mavyret can cause hepatitis B to become active again if you have had it in the past.

The sections below are summarized in plain English from glecaprevir/pibrentasvir's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.

Side Effects (from patient reports)

Based on 8,300 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for glecaprevir/pibrentasvir, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS)

Serious Warnings

Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.

Known Drug Interactions

major rifampin

Antimycobacterials: Rifampin ↓ glecaprevir ↓ pibrentasvir Coadministration is contraindicated because of potential loss of therapeutic effect [see Contraindications ( 4 ) ] .

Mechanism: Rifampin lowers the levels of the hepatitis C medicine in your body. This makes the treatment less effective and may prevent it from curing the infection.

major rosuvastatin

Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.

Mechanism: These drugs can cause rosuvastatin levels to rise in your body, which may increase the risk of side effects.

major rosuvastatin/ezetimibe

Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.

Mechanism: These hepatitis C drugs block the pathways your body uses to remove rosuvastatin, leading to higher levels of the statin in your blood. This can increase your risk for serious side effects.

moderate cyclosporine

Immunosuppressants: Cyclosporine ↑ glecaprevir ↑ pibrentasvir MAVYRET is not recommended for use in patients requiring stable cyclosporine doses > 100 mg per day.

Mechanism: Cyclosporine causes the levels of glecaprevir and pibrentasvir to increase in your body. This happens because cyclosporine interferes with how the body processes these medications.

moderate darunavir

glecaprevir/pibrentasvir ↑ glecaprevir ↑ pibrentasvir Co-administration of darunavir/ritonavir with glecaprevir/pibrentasvir is not recommended.

Mechanism: Darunavir increases the amount of glecaprevir and pibrentasvir that stays in your body. This can make the hepatitis C medication more likely to cause side effects.

Check all your medications →

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

How long will I need to take Mavyret?
The usual treatment time is 8 to 16 weeks, depending on your specific situation.
Can I take Mavyret if I have kidney problems?
Yes, you can usually take Mavyret if you have kidney problems. Follow the dosage your doctor prescribes.
Can I take Mavyret if I have HIV?
Yes, you can usually take Mavyret if you have HIV. Follow the dosage your doctor prescribes.
What should I do if I vomit after taking Mavyret?
If you vomit shortly after taking Mavyret, talk to your doctor. You may need to take another dose.
Can I drink alcohol while taking Mavyret?
Talk to your doctor about drinking alcohol while taking Mavyret. They can advise you based on your liver health.
Will Mavyret interact with other medications I am taking?
Mavyret can interact with other medications. Tell your doctor about all the medicines you take, including over-the-counter drugs and supplements.
How will I know if Mavyret is working?
Your doctor will do blood tests to check the amount of hepatitis C virus in your blood. This will show if the medicine is working.
What if I have side effects from Mavyret?
Tell your doctor about any side effects you have while taking Mavyret. They can help you manage them.
Can children take Mavyret?
Yes, Mavyret can be used in children 3 years and older.
Is there a generic version of Mavyret?
No, there is currently no generic version of Mavyret available.
What are the common side effects of glecaprevir/pibrentasvir?
The registry lists Headache, Feeling tired, Nausea among the most-reported FAERS reaction terms for glecaprevir/pibrentasvir. The compiled record contains 8,300 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does glecaprevir/pibrentasvir interact with other medications?
The registry has 38 documented interaction rows for glecaprevir/pibrentasvir. Notable source-record pairings include rifampin, rosuvastatin, rosuvastatin/ezetimibe. These rows are not a complete medication review.
What drug class is glecaprevir/pibrentasvir?
glecaprevir/pibrentasvir belongs to the NS3/4A/NS5A Inhibitor (HCV) drug class. It requires a prescription (Rx). Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6.
What pregnancy or breastfeeding source fields are listed for glecaprevir/pibrentasvir?
The FDA label for glecaprevir/pibrentasvir contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Related Medications in NS3/4A/NS5A Inhibitor (HCV)

Other drugs grouped near glecaprevir/pibrentasvir - same-class peers and common alternatives.

acyclovir

Zovirax

Acyclovir is an antiviral medicine.

Compare with glecaprevir/pibrentasvir →

albendazole

Albenza

Albendazole is a medicine that fights parasites.

Compare with glecaprevir/pibrentasvir →

amphotericin B

Ambisome, Fungizone

Amphotericin B liposome is an antifungal medicine.

Compare with glecaprevir/pibrentasvir →

anidulafungin

Eraxis

Eraxis is an antifungal medicine.

Compare with glecaprevir/pibrentasvir →

atovaquone/proguanil

Malarone

Malarone is a drug used to prevent and treat malaria.

Compare with glecaprevir/pibrentasvir →

Compare glecaprevir/pibrentasvir vs acyclovir side-by-side →

Medication Guides

Understanding Drug Interactions

How CYP450 enzymes, inhibitors, and inducers affect your medications

Generic vs Brand Name Drugs

FDA requirements, cost savings, and when the difference matters

Narrow Therapeutic Index Drugs

FDA bioequivalence and label-record context for narrow therapeutic index medicines

Common Drug Interactions

Dangerous medication combinations and how to protect yourself

Save on glecaprevir/pibrentasvir

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Check Prices on GoodRx →

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for glecaprevir/pibrentasvir

The FDA label for glecaprevir/pibrentasvir (sold under brand names such as Mavyret) classifies it as a prescription-only medication in the NS3/4A/NS5A Inhibitor (HCV) class. Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. Official labeling lists 3 commonly reported side effects, including Headache, Feeling tired, Nausea.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 8,300 voluntary reports. The database also lists 38 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: June 10, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Read our methodology - how this data is sourced, computed, and verified.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page